<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ASAP Discovery Outputs on ASAP Discovery Consortium</title><link>https://asapdiscovery.org/outputs/</link><description>Recent content in ASAP Discovery Outputs on ASAP Discovery Consortium</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><atom:link href="https://asapdiscovery.org/outputs/index.xml" rel="self" type="application/rss+xml"/><item><title>Viral Families</title><link>https://asapdiscovery.org/outputs/viral-families/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/viral-families/</guid><description>Coronaviruses Flaviviruses Picornaviruses Influenza (not funded by AViDD U19)
Togaviruses (collaboration with NCATS)
Other viral families ASAP Discovery is greatly interested in expanding its efforts to target other viral families not listed here, and is actively seeking funding to enable this expansion in scope.</description></item><item><title>Targeting Opportunities</title><link>https://asapdiscovery.org/outputs/targeting-opportunities/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/targeting-opportunities/</guid><description/></item><item><title>Structures</title><link>https://asapdiscovery.org/outputs/structures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/structures/</guid><description>Program 1 Program 2</description></item><item><title>Molecules</title><link>https://asapdiscovery.org/outputs/molecules/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/molecules/</guid><description>SARS-CoV-2 ns3 Mac1 macrodomain Program 2</description></item><item><title>Mutation Data</title><link>https://asapdiscovery.org/outputs/mutation-data/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/mutation-data/</guid><description> Coronavirus MERS-CoV/SARS-CoV-2 Mpro Coronavirus nsp3-mac1 Item 3</description></item><item><title>Target Product Profiles (TPPs)</title><link>https://asapdiscovery.org/outputs/target-product-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-product-profiles/</guid><description/></item><item><title>Target Candidate Profiles (TCPs)</title><link>https://asapdiscovery.org/outputs/target-candidate-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-candidate-profiles/</guid><description/></item><item><title>Assay Cascades</title><link>https://asapdiscovery.org/outputs/assay-cascade/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-cascade/</guid><description>Coronavirus MERS-CoV/SARS-CoV-2 Mpro Coronavirus nsp3-mac1 Item 3</description></item><item><title>Target Enabling Packages (TEPs)</title><link>https://asapdiscovery.org/outputs/target-enabling-packages/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-enabling-packages/</guid><description>Enterovirus D68 3C protease Status: In progress Gene: NP_740535.1 &amp;nbsp; Uniprot: A0A059XIJ7 &amp;nbsp; EC: Target Nominator: Alpha Lee Target PI: Frank von Delft Therapeutic Area(s): Infectious diseases Disease Relevance: 3C proteases are a clinically validated target. Viral family: coronaviridae Viruses: enterovirus D68 Summary of Project The conserved 3C protease of enterovirus D68 is required to cleave the nonstructural region of the viral polyprotein. This TEP aims to provide early tools for structure-based discovery of 3C protease inhibitors, including purification protocols of recombinant proteins, and reproducible crystallisation condition suitable for X-ray crystallography fragment screening.</description></item><item><title>Hit-to-Lead</title><link>https://asapdiscovery.org/outputs/hit-to-lead/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/hit-to-lead/</guid><description>Program 1 Program 2</description></item><item><title>Lead Optimization</title><link>https://asapdiscovery.org/outputs/lead-optimization/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/lead-optimization/</guid><description>Program 1 Program 2</description></item><item><title>Investigational New Drug (IND) filings</title><link>https://asapdiscovery.org/outputs/investigational-new-drugs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/investigational-new-drugs/</guid><description>Program 1 Program 2</description></item><item><title/><link>https://asapdiscovery.org/outputs/img/icons/readme/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/img/icons/readme/</guid><description>Icons from The Noun Project Icons are CC-BY from The Noun Project
Credits (for CC-BY acknowledgments) assay-cascade.png : noun-chemistry-2954755 : Chemistry by Icon Factory from Noun Project clinical-trails.png : noun-medical-1053629 : medical by Raymond from Noun Project data.png : noun-save-5021426 : Save by Cetha Studio from Noun Project disease.png : noun-medical-3923610 : medical by Royyan Wijaya from Noun Project DMS.png : noun-mutation-4374976 : mutation by Adrien Coquet from Noun Project hit-to-lead.</description></item></channel></rss>